Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: d6-tetrabenazine, deutetrabenazine
Trade Name: Austedo
Date Designated: 11/05/2014
Orphan Designation: Treatment of Huntington's Disease
Orphan Designation Status: Designated/Approved
Teva Branded Pharmaceutical Products R&D, Inc.
3333 N. Torrey Pines Court
Suite 400
La Jolla, California 92037
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: d6-tetrabenazine, deutetrabenazine
Trade Name: Austedo
Marketing Approval Date: 04/03/2017
Approved Labeled Indication: Treatment of chorea associated with Huntington¿s disease
Exclusivity End Date: 04/03/2024 
Exclusivity Protected Indication* :  Treatment of chorea associated with Huntington¿s disease
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-